3.77

2.45% 0.09

After Hours: 3.77

Sight Sciences Inc (SGHT)

Overview News Price History Option Chain Financials Why SGHT Down? Discussions Forecast

Sight Sciences Inc stock is traded at $3.77, with a volume of 536.90K. It is up +2.45% in the last 24 hours and down -26.94% over the past month. Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Previous Close:

$3.68

Open:

$3.78

24h Volume:

536.90K

Relative Volume:

1.65

Market Cap:

$203.60M

Revenue:

$77.36M

Net Income/Loss:

$-38.43M

P/E Ratio:

-5.0891

EPS:

-0.7408

Net Cash Flow:

$-29.92M

1W Performance:

-2.08%

1M Performance:

-26.94%

6M Performance:

+9.59%

1Y Performance:

+57.08%

1-Day Range:

$3.66

$4.04

1-Week Range:

$3.63

$4.11

52-Week Range:

$2.03

$9.2362

Sight Sciences Inc Stock (SGHT) Company Profile

Name

Sight Sciences Inc

Sector

Healthcare (1114)

Industry

Medical Devices (143)

Phone

(415) 889-0550

Address

4040 CAMPBELL AVE,, MENLO PARK

Employee

186

Twitter

Next Earnings Date

2025-03-05

Latest SEC Filings

SGHT's Discussions on Twitter

Compare SGHT vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SGHT Sight Sciences Inc	3.77	198.74M	77.36M	-38.43M	-29.92M	-0.7408
ABT Abbott Laboratories	102.67	177.03B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	328.59	124.89B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	86.65	110.08B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	62.75	93.53B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	80.08	45.84B	6.07B	1.06B	1.34B	1.8063

Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-26	Upgrade	Piper Sandler	Neutral → Overweight
Aug-08-25	Upgrade	Lake Street	Hold → Buy
Dec-06-24	Initiated	UBS	Buy
Nov-04-24	Downgrade	Lake Street	Buy → Hold
Aug-21-24	Initiated	Lake Street	Buy
Sep-12-23	Downgrade	BofA Securities	Neutral → Underperform
Sep-12-23	Downgrade	Piper Sandler	Overweight → Neutral
Sep-12-23	Downgrade	William Blair	Outperform → Mkt Perform
Aug-24-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-10-23	Downgrade	Citigroup	Buy → Neutral
Jan-06-23	Upgrade	Stifel	Hold → Buy
Oct-04-22	Initiated	Needham	Hold
Jul-26-22	Initiated	Stifel	Hold
Feb-03-22	Initiated	William Blair	Outperform
Jan-07-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight

View All

Sight Sciences Inc Stock (SGHT) Latest News

Mar 30, 2026

Sight Sciences wins $34M in Alcon patent case, ongoing royalty - Investing.com Australia

Mar 30, 2026

Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th - Yahoo! Finance Canada

Mar 30, 2026

Del. Judge Upholds $34M Verdict In Glaucoma Patent Feud - Law360

Mar 30, 2026

Published on: 2026-03-31 02:42:17 - baoquankhu1.vn

Mar 30, 2026

Sight Sciences Wins $34 Million Patent Infringement Case Against Alcon, Secures Ongoing Royalties Through 2028 - Minichart

Mar 30, 2026

Sight Sciences U.S. district court issued order on post-trial motions in patent infringement case against Alcon originally filed on Sep 16, 2021 - marketscreener.com

Mar 30, 2026

Sight Sciences U.S. District Court Issued Order On Post-Trial Motions In Patent Infringement Case Against Alcon Originally Filed On Sep 16, 2021 - TradingView

Mar 30, 2026

Sight Sciences Wins Infringement Lawsuit Against Alcon - National Today

Mar 30, 2026

Sight Sciences Wins Key Patent Ruling in Glaucoma Case - TipRanks

Mar 30, 2026

Sight Sciences (NASDAQ: SGHT) awarded $34M plus 10% Hydrus royalties - Stock Titan

Mar 30, 2026

Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent - marketscreener.com

Mar 30, 2026

Court keeps $34 million award, 10% royalties in eye-stent patent fight - Stock Titan

Mar 30, 2026

Mar 28, 2026

Growth Value: Is Sight Sciences Inc on track to beat earnings2026 Movers & Fast Gain Stock Trading Tips - baoquankhu1.vn

Mar 28, 2026

Mar 26, 2026

Sight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Mar 26, 2026

Mar 25, 2026

Aug Ideas: Is Sight Sciences Inc in a consolidation phase2026 Highlights & High Accuracy Investment Signals - baoquankhu1.vn

Mar 25, 2026

Mar 24, 2026

Sight Sciences Inc stock faces pressure amid weak Q4 guidance and slowing growth in eye care devices - AD HOC NEWS

Mar 24, 2026

Mar 18, 2026

Citigroup maintains Sight Sciences (SGHT) neutral recommendation - MSN

Mar 18, 2026

Sight Sciences outlines $82M–$88M 2026 revenue target while expanding interventional dry eye strategy - MSN

Mar 18, 2026

Mar 17, 2026

Can Sight Sciences Inc weather a recession2026 Technical Overview & Weekly High Conviction Trade Ideas - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

Earnings call transcript: Sight Sciences beats Q4 2025 forecasts, stock rises - Investing.com Nigeria

Mar 16, 2026

Mar 14, 2026

Prosight Management LP Sells 431,746 Shares of Sight Sciences, Inc. $SGHT - MarketBeat

Mar 14, 2026

Mar 12, 2026

Morgan Stanley Sticks to Its Hold Rating for Sight Sciences (SGHT) - The Globe and Mail

Mar 12, 2026

Mar 11, 2026

Stock Report: Can Sight Sciences Inc weather a recession2025 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn

Mar 07, 2026

Mar 06, 2026